Biogen’s new spinoff Bioverativ will be trading on the Nasdaq next from the start of month with two products, $325 million in the bank, hundreds of staffers…

Ionis, fresh from its approval of Spinraza with Biogen, says it is seeking to get its heart drug volanesorsen in front of the FDA as soon as possible, as it…

Merck KGaA has paid Vertex Pharmaceuticals $230 million (€219 million) upfront for the rights to four cancer programs.

Fresh off its $5.2 billion deal for Ariad this week, Takeda shows no signs of slowing down in the deal stakes as it announces a collab and potentially a future…

Everyone wanted to hear Gilead at the JPM San Francisco meeting yesterday, but it did not come up with what many investors wanted to hear: a major deal.

The University of Pittsburgh is deepening its ties with German pharma Bayer as the two pen a research pact for heart, lung and blood disease indications.

Efferent Labs has inked a deal with Evotec to develop implantable biosensor technology. The device contains living cells to measure cellular function in vivo.

Allergan's drive to bulk up its R&D pipeline accelerated in 2016 and looks set to follow a similar course this year.

Moderna, often accused of being secretive after failing to reveal, publicly at least, its pipeline of meds, finally did so yesterday with its candidates…

Deals